相关实验视频
Updated: Jun 6, 2025

08:47
Intracranial Injection of Adeno-associated Viral Vectors
Published on: November 17, 2010
47.4K
在治疗中的腺相关病毒载体
Aysilu I Mullagulova1, Elena E Timechko2, Valeriya V Solovyeva1
1Institute for Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia.
International journal of molecular sciences
|November 27, 2024
概括
使用腺关联病毒 (AAV) 载体的基因疗法为治疗提供了一种有前途的新方法,特别是对于抗传统药物耐药的患者. 这些载体使个性化治疗能够有效地减少活动并改善患者的治疗结果.
科学领域:
- 神经科学是一个神经科学.
- 基因治疗 基因治疗
- 分子生物学分子生物学
背景情况:
- 是一种神经系统疾病,由反复发作来定义.
- 对抗药物的耐药性影响了相当一部分患者.
- 包括基因疗法在内的新型治疗策略对于治疗耐药性至关重要.
研究的目的:
- 审查腺相关病毒 (AAV) 载体在的基因治疗中的应用.
- 突出AAV载体在治疗方面的优势.
- 讨论以AAV为基础的基因治疗的未来方向.
主要方法:
- 对症基因治疗中AAV载体应用的当前文献的综述.
- 对AAV载体特征的分析,包括转导效率,免疫性和血清型多样性.
- 探索治疗症中AAV介导基因疗法的治疗目标和策略.
主要成果:
- AAV载体在转导低免疫性和细胞毒性神经元组织方面表现出高效率.
- AAV血清型和基因组结构的多样性促进了个性化的治疗.
- 潜在的治疗策略包括调节神经,离子通道,转录因子,神经营养因子和使用反感性寡核酸.
结论:
- AAV载体对于开发针对的个性化和有效的基因疗法具有显著的潜力.
- 这些载体为减少发作的严重程度和改善各种病病因患者的预后提供了一个有希望的途径.
- 对基于AAV的基因疗法的持续研究对于推进治疗至关重要.
相关概念视频
Antiepileptic Drugs: Glutamate Antagonists
283
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
283
Arteries of the Lower Limbs
177
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
177
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
251
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
251

